Cell biologists at Cambridge University have received £6 million venture capital to form a spin-out company that will focus on methods for repairing damaged DNA in cancer patients, it was announced on 25 August.
The company, MISSION Therapeutics, will attempt to develop the results of Stephen Jackson’s team at the Gurdon Institute, University of Cambridge. Their research on the ubiquitin enzyme pathways that control cellular responses to DNA damage has been funded by Cancer Research UK.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.